← Hims Hers Health overview

Hims Hers Health vs Option Care Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hims Hers Health Inc (HIMS)

Q3 2026
▲2▼2

Hims & Hers grew fast but faced FTC suit and cash burn

  • Strong revenue and subscriber growth Revenue jumped 38% to $753.2M and subscribers rose 18.5% to about 2.9 million, prompting management to raise full-year guidance to $3.1–3.3 billion. This shows the core business is still expanding quickly.

    It explains the main positive force behind the quarter's results.

  • GLP-1 momentum and international expansion Barclays raised its price target to $39, citing momentum in weight-loss drugs (GLP-1s), helped by the Novo Nordisk partnership and the Eucalyptus acquisition that expands into the UK, Australia, and Canada.

    It highlights a key growth driver and analyst optimism that supported the stock.

  • FTC lawsuit and legal probes An FTC lawsuit over health-data sharing and deceptive billing sank the stock 14.7% and triggered multiple law-firm investigations. This regulatory risk weighed heavily on investor sentiment.

    It was the biggest negative event that hurt the stock during the quarter.

  • Financial deterioration and operational issues Q2 swung to a $0.37 loss, gross margin fell to about 64%, free cash flow turned negative $68M, and Visa placed HIMS in a chargeback-monitoring program. Leadership departures and a 51% yearly stock drop fueled takeover talk.

    It shows the financial and operational setbacks that pressured the stock.

August 2026
▼2▲1

Hims & Hers: strong sales but losses, legal and payment risks hit stock

  • Revenue and subscriber growth beat expectations Revenue rose 38% to $753.2M, beating estimates, and full-year guidance was raised to $3.1–$3.3B. Subscribers grew 18.5% to about 2.9 million, showing demand for its health and weight-loss services remains strong.

    This is the main positive force behind the stock, showing the business is still growing quickly.

  • Profit turned to loss as costs and margins worsened Q2 swung to a $0.37 loss from a $0.17 profit, gross margin fell to about 64% from 76%, free cash flow turned negative $68M, and operating expenses jumped 48.4%. This shows growth is coming at a high cost.

    This explains why the stock fell despite strong revenue, as profitability and cash flow deteriorated.

  • Visa dispute program and lawsuits raise risk Visa placed HIMS in a dispute-monitoring program over weight-loss subscription chargebacks, while FTC, state, and class-action lawsuits over billing and privacy raise costs and reputational risk. These issues threaten its payment processing and trust with customers.

    This is a new negative development that adds to legal and operational uncertainty, weighing on the stock.

  • Leadership change and takeover talk amid weak stock The chief accounting officer is departing, and the stock fell 51% in a year, prompting takeover speculation despite CEO voting control and about $1B convertible debt. JPMorgan initiated at Neutral with a $32 target, citing execution risk in branded GLP-1s.

    This captures the mixed sentiment: management turnover and a weak stock invite takeover talk, but analysts see execution risk.

Latest
▼2

HIMS: legal risk, leadership exit, and a 51% slump reshape the story

  • Privacy investigations and class action raise legal risk Law firms are investigating and suing Hims & Hers over claims it shared users' private health data and mishandled billing. Legal fights like this can bring fines, payouts, and bad publicity, which weighs on the stock because investors worry about cost and reputation.

    New legal and regulatory threats are a fresh, material drag on HIMS.

  • Chief accounting officer to leave in October Hims & Hers said its chief accounting officer, Irene Becklund, will depart on October 9, 2026, after seven years. The CFO will cover the role while a replacement is found. A key finance leader leaving adds uncertainty, which can pressure the stock.

    A senior finance departure is a new event that creates uncertainty for investors.

  • Stock down 51% makes HIMS a takeover candidate After a 51% one-year drop, Hims & Hers is being talked about as a possible acquisition target for Amazon, UnitedHealth, CVS, or Pfizer, though its CEO controls voting shares and about $1 billion in convertible debt complicates any deal. Takeover talk can support the stock, but the weak price and debt are negatives.

    The steep decline and buyout speculation are new and directly shape how investors value HIMS.

  • JPMorgan starts coverage at Neutral with $32 target JPMorgan began covering Hims & Hers with a Neutral rating and a $32 price target, saying growth is strong but the shift to branded weight-loss drugs like Wegovy carries execution risk. A neutral start with a target near the current price gives little fresh upside push.

    A major bank's first rating is a new signal that frames the bull and bear case.

▼3▲1

Visa billing crackdown and FTC lawsuit hit HIMS; growth stays strong

  • Visa puts HIMS in dispute-monitoring program Visa placed Hims & Hers in its Acquirer Monitoring Program after a surge in credit-card disputes tied to weight-loss subscriptions, with a possible $75,000 penalty and a requirement to keep disputes below 1.5% for three months. This threatens billing reliability and could slow subscriber growth, pushing the stock down.

    This is the main new negative event this period and directly pressures HIMS's price.

  • FTC and state regulators escalate legal action The FTC and state regulators filed a civil enforcement action, and a consumer class action targets privacy and subscription practices. The CEO says the FTC misunderstands the company, but the legal fight adds costs and reputational risk that weigh on the stock.

    This is a new escalation of the legal pressure that is a core driver of HIMS's risk profile.

  • Q2 revenue jumps 38% and outlook raised Hims & Hers raised its 2026 revenue outlook to $3.1–$3.3 billion after Q2 sales rose 38.2% to $753.2 million, beating estimates. Subscribers grew 18.5% to about 2.9 million, showing demand is still strong and supporting the stock.

    This is the main new positive fundamental update this period and shows the growth story remains intact.

  • Margins shrink and cash burn deepens Gross margin fell to 63.8% from 76%, operating expenses rose 48.4%, and free cash flow was negative $68 million with an $86.3 million net loss. The company is spending heavily to grow, which pressures profits and keeps the stock volatile.

    This is the key counterweight to the revenue beat and explains why the stock still faces pressure.

▼2

HIMS Q2 loss and margin hit overshadow revenue beat

  • Q2 loss and margin collapse Hims & Hers reported a second-quarter loss of $0.37 per share, swinging from a $0.17 profit a year earlier. Gross margin fell to 64% from 76%, hit by an $81 million one-time cost tied to the Eucalyptus acquisition, a weight-loss strategy shift, and FTC legal reserves. This profit miss is what pushed the stock down.

    The earnings miss and margin drop are the main new financial event driving the stock lower this period.

  • Revenue beat and raised guidance Revenue rose 38% to $753.2 million, beating the roughly $699 million analysts expected, and the company raised its full-year revenue outlook to $3.1 billion to $3.3 billion. This shows demand is still strong, but investors focused on the loss and costs, so the stock still fell.

    It is the positive counterweight in the same earnings report and explains why the selloff was not larger.

  • CEO defends FTC lawsuit, touts cheaper GLP-1s CEO Andrew Dudum said the FTC lawsuit is more about publicity than a real resolution, and he expects cash-paying patients to eventually pay $40 to $50 a month for branded weight-loss drugs, down from $150 to $200. Cheaper pricing could boost demand, but the lawsuit still threatens fines and trust.

    It updates the biggest legal overhang and gives a concrete path to lower prices that could help future demand.

  • Weight-loss pill market cost pressure Hims & Hers and Novo Nordisk both fell even after strong growth, as investors worried about rising costs in the weight-loss pill market. Novo Nordisk's Wegovy pill sales missed expectations, adding to concerns that the branded GLP-1 push may be less profitable than hoped.

    It shows the cost and competition pressure in the core weight-loss business that is weighing on HIMS shares.

July 2026
▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

Option Care Health Inc (OPCH)

Q3 2026
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

August 2026
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

Latest
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.